Edition:
United States

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

13.15USD
24 Feb 2017
Change (% chg)

$-0.24 (-1.79%)
Prev Close
$13.39
Open
$13.31
Day's High
$13.48
Day's Low
$13.06
Volume
1,543,913
Avg. Vol
1,536,869
52-wk High
$54.78
52-wk Low
$11.37

Latest Key Developments (Source: Significant Developments)

Endo's restructuring actions to reduce workforce by nearly 90 full-time positions
Thursday, 26 Jan 2017 06:30am EST 

Endo International Plc : Endo announces actions to drive greater efficiency and business alignment . Endo International - Restructuring actions primarily relate to co's corporate functions and Branded Pharmaceutical research and development functions in Malvern, PA and Chestnut Ridge, NY . Endo International Plc - Restructuring actions will reduce Endo's work force by approximately 90 full-time positions . Says Endo expects to realize approximately $40 million to $50 million in annual run rate pre-tax cost savings by q4 of 2017 . Endo International expects to realize about $40 million to $50 million in annual run rate pre-tax cost savings by Q4 of 2017 . Endo International Plc - Restructuring actions will result in restructuring cash charges of approximately $15 million to $20 million .Endo International expects to invest portion of cost savings in co's core product franchises and new product development programs.  Full Article

Endo says appointed Blaise Coleman as CFO
Tuesday, 20 Dec 2016 07:30am EST 

Endo International Plc : Endo International Plc - coleman has been serving as Endo's interim chief financial officer since November 22, 2016 .Endo announces appointment of Blaise Coleman as chief financial officer.  Full Article

BioDelivery Sciences reacquires license to BELBUCA from Endo Pharmaceuticals
Thursday, 8 Dec 2016 06:00am EST 

BioDelivery Sciences International Inc - : BioDelivery Sciences reacquires license to BELBUCA™ from Endo Pharmaceuticals . Endo will not be obligated to any future milestone payments to BDSI . Return of BELBUCA is expected to be accretive by improving BDSI's net income and earnings per share in 2017 . BDSI will also explore other options for longer-term growth for BELBUCA both within and ex-U.S . As a result of agreement, world-wide rights to BELBUCA will be transferred back to BDSI . Agreement goes into effect on January 6, 2017. . Specific financial terms of agreement have not been disclosed . Financial terms do not have a material impact on company's going forward cash runway . Total cost of transaction to BDSI will not materially impact BDSI's cash flow going forward .BDSI will not be responsible for future royalties or milestone payments to Endo.  Full Article

Endo International eliminating 375-member U.S. branded pain sales field force
Thursday, 8 Dec 2016 06:00am EST 

Endo International Plc - : It is eliminating its 375-member U.S. Branded pain sales field force . The strategic actions are expected to result in restructuring charges of approximately $62 million . Restructuring expected to provide approximately $90 million to $100 million in annual run rate pre-tax gross cost savings in 2017 . Anticipates a portion of cost savings to be redeployed in 2017 to support pursuit of development and approval of Xiaflex . Legacy pain portfolio products - including Opana ER and Percocet, among others will be managed as mature brands .Restructuring charges include a $40 million non-cash intangible asset impairment charge.  Full Article

Endo reports third quarter 2016 financial results
Tuesday, 8 Nov 2016 06:30am EST 

Endo International Plc : Endo International Plc - Company reaffirms full year 2016 revenues and adjusted diluted EPS financial guidance . FY2016 earnings per share view $4.55, revenue view $3.93 billion -- Thomson Reuters I/B/E/S . Endo reports third quarter 2016 financial results . Q3 adjusted earnings per share $1.01 from continuing operations . Q3 GAAP loss per share $0.86 from continuing operations . Q3 revenue $884 million versus I/B/E/S view $862.3 million .Q3 earnings per share view $0.81 -- Thomson Reuters I/B/E/S.  Full Article

Endo International names Paul Campanelli CEO
Friday, 23 Sep 2016 07:00am EDT 

Endo International PLC : Endo names Paul Campanelli president and chief executive officer . Company affirms Q3 and full year 2016 financial guidance . Campanelli succeeds Rajiv De Silva, who has stepped down as president, CEO and a member of board . Q3 earnings per share view $0.82, revenue view $864.5 million -- Thomson Reuters I/B/E/S .FY2016 earnings per share view $4.56, revenue view $3.93 billion -- Thomson Reuters I/B/E/S.  Full Article

Vivus says extends return date of Stendra commercial rights
Monday, 29 Aug 2016 04:30pm EDT 

Vivus Inc [VVUS.O] : Vivus inc says extends return date of stendra commercial rights . Extension of termination date of license agreement between auxilium and vivus for stendra u.s. And canadian commercial rights through sept 30, 2016 .Vivus inc says preparing to commercialize stendra in u.s. While maintaining discussions to license or sell stendra's u.s. Commercialization rights.  Full Article

Endo International says President and CEO Adopts 10B5-1 trading plan
Thursday, 18 Aug 2016 04:05pm EDT 

Endo International Plc : Says CEP Rajiv De Silva has entered into a rule 10b5-1 stock trading plan in connection with his year-end tax planning . Under terms of de silva's stock plan, third-party broker will sell up to 13,500 endo shares owned by de silva . Endo international says de silva's stock being sold, represents about 4 percent of de silva's total endo stock ownership .Says ceo's stock trading plan will be completed in september 2016.  Full Article

Endo to continue collecting, analyzing data relating to OPANA ER
Friday, 12 Aug 2016 07:00am EDT 

Endo International Plc : Endo announces OPANA ER regulatory update . Plans to continue collecting and analyzing epidemiological data relating to OPANA ER . Financial projections for 2016 did not assume approval of SNDA . Endo announces OPANA ER regulatory update .Says has decided to withdraw its supplemental new drug application (SNDA) relating to specific abuse deterrent labeling for OPANA ER.  Full Article

Endo posts Q2 adj. earnings $0.86/shr from continuing operations
Monday, 8 Aug 2016 04:28pm EDT 

Endo International Plc : Endo reports second quarter 2016 financial results . Q2 adjusted earnings per share $0.86 from continuing operations . Q2 revenue $921 million versus I/B/E/S view $863.9 million . Q2 GAAP earnings per share $1.75 from continuing operations . Q2 earnings per share view $0.74 -- Thomson Reuters I/B/E/S . During Q2 2016, company recorded pre-tax, non-cash impairment charges of $40.0 million .Affirming our full year 2016 revenue and adjusted diluted EPS financial guidance.  Full Article

More From Around the Web

Endo International CEO steps down, Campanelli named successor

Endo International Plc said Chief Executive Rajiv De Silva had stepped down and would be replaced by generics division head Paul Campanelli, as the drugmaker grapples with a large debt load and mounting pressure on some of its drug prices.